Other Transaction Agreement 140D042690022
Award Date 9/2/26
Potential Completion Date 9/1/29
Potential Value $10M
Funding Federal Agency
Contracting Federal Agency
Awardee
Ultimate Awardee
Not listed NAICS Category
Not listed Set-Aside Type
Not listed Federal Contract Vehicle
- Not listed
Extent Competed
Competed
Major Defense Program
Not listed Pricing Type
Other
Place of Performance
Dorchester, MA 02125, USA
Solicitation Procedures
Program Solicitation
Number Of Offers Received
Not listed
Legislative Mandate
Not listed National Interest Action
Not listed Research Type
Not listed Primary Consortia Member
Not listed Similar Awards
- The National Institutes of Health awarded an Other Transaction Agreement to Terasaki Institute For Biomedical Innovation on July 31, 2026, for PROMETHEUS (Personalized & Regenerative Organ Manufacturing Enhanced Through Hypoimmunogenic Engineered Universal Cells), with a ceiling value of $19,796,008.37. This OTA sits outside the FAR and operates under alternative transaction authority. Performance runs through July 30, 2031, at Terasaki's facility in Woodland Hills, California. The program...
- The National Institutes of Health awarded an Other Transaction Agreement to Immunovec, Inc. on September 22, 2025, with a ceiling value of $40.7 million for the SPECIFIC (Specialized, Polymer-Based, Efficient, Cell Type-Targeted Injections for Innovative Cures) program. The agreement sits outside the Federal Acquisition Regulation and operates under OTA statutory authority. Performance runs through September 21, 2031, with work performed in Malibu, California. The program focuses on...
- The National Institutes of Health awarded an Other Transaction Agreement to Global Life Sciences Solutions USA LLC for $40,130,860 to develop CRISPR delivery and manufacturing innovation for minimal-cost cancer and HIV therapies via in vivo immune engineering, with an award date of September 25, 2025. The agreement runs through September 24, 2031 and is performed in Marlborough, Massachusetts. As an OTA, this agreement operates outside the Federal Acquisition Regulation and represents a...
- The National Institutes of Health awarded an Other Transaction Agreement to Syracuse University for $2,256,884 on February 20, 2026, to develop lego-like assembly of perfusable extracellular matrix cubes to generate tissue-agnostic, suturable, organ-sized, viable and functional grafts. The agreement sits outside the Federal Acquisition Regulation as an OTA. Work will be performed in Syracuse, New York, with an ultimate completion date of February 19, 2029. This represents a research and...
- The National Institutes of Health (NIH) has awarded an Other Transaction Agreement (OTA) valued at $48M to Kernal Biologics, Inc., a Cambridge, Massachusetts-based biotechnology firm, for selective mRNA-lipid nanoparticle (LNP) engineering aimed at cost-effective in situ CAR T-cell programming. The contract, awarded on September 16, 2025, extends through September 15, 2031, and represents a non-traditional acquisition vehicle that allows the NIH greater flexibility in structuring terms and...
- Acrocyte Therapeutics Inc. has been awarded an Other Transaction Agreement valued at $4.37M by the National Institutes of Health (NIH) to develop rapid and reliable autologous cell screening and expansion technologies for organoid therapy. The contract, awarded on March 19, 2026, with an ultimate completion date of March 18, 2029, will be performed at the company's facility in Fremont, California. This effort supports NIH's broader mission to advance regenerative medicine and cell-based...
- <p>The National Institutes of Health awarded an Other Transaction Agreement to Lacristat LLC for COSMIC (Closed-Loop Sensing and Microdosing for Dry Eye and Systemic Disease Management) on January 29, 2026, with a ceiling value of $16,356,306.90. The agreement sits outside the Federal Acquisition Regulation framework and is structured as an OTA prototype or R&D effort. Performance will occur in Chicago, Illinois. The ultimate completion date is January 28, 2030.</p>
- The National Institutes of Health awarded an Other Transaction Agreement to Massachusetts Institute of Technology on February 27, 2026, for the Self-Powered, Transmitting Lacrimal Artificial Sensor (SPOT-LAS) effort under the OCULAB program, with a ceiling value of $10,091,432 and an ultimate completion date of February 26, 2030. This OTA sits outside the FAR and provides NIH with flexible contracting authority for prototype development and biomedical research. Performance occurs in Cambridge,...
- The National Institutes of Health awarded an Other Transaction Agreement to President and Fellows of Harvard College, operating through Harvard Medical School, with a ceiling value of $4,399,574 on July 24, 2026. The OTA, designated HARVARD – PROPEL, is scheduled for completion by July 23, 2027. Work is performed in Boston, Massachusetts. As an OTA, this award sits outside the Federal Acquisition Regulation and operates under alternative transaction authority. The source does not specify the...
- The National Institutes of Health awarded an Other Transaction Agreement to Vitakey Inc. valued at $13,823,026.89 on May 29, 2025, for the ARPA-H Nutrition Base Satiety Modulation program. This OTA sits outside the FAR and follows the regulatory framework governing Other Transaction Agreements. The agreement runs through November 28, 2031. Place of performance is Washington, DC 20036. Vitakey Inc., a for-profit biotechnology firm based in Washington, D.C., specializes in advanced...